Last verified on June 19, 2017Please note that the ABR policies and requirements related to Authorized User (AU) eligibility status remain unchanged from the text below, which was sent to radiation oncology program directors in April 2006. NRC recognition for the American Board of Radiology for residency training and experience in the therapeutic administration of unsealed byproduct material for which a written directive is required. The final version of changes in the Nuclear Regulatory Commission (NRC) rules, which govern the training and experience required to administer the types of radioactive materials commonly used in radiation oncology and nuclear radiology for the treatment of several different malignancies, was published on March 30, 2005, in the Federal Register. The NRC accepts ABR certification as evidence that a practitioner is properly trained to safely and effectively use therapeutic radioactive materials. The ABR requires that resident training and experience, as well as the materials on which the ABR examines, match NRC regulations. These regulations pertain to training and experience in the therapeutic administration of unsealed byproduct material (10 CFR 35.390), as well as the use of manual brachytherapy sources (10 CFR 35.490) and remote afterloader units, teletherapy units, and gamma stereotactic radiosurgery units (10 CFR 35.690). Each of these modalities requires a written directive as described in 10 CFR 35.40. The ABR and the Radiation Oncology RRC will maintain consistency with these requirements. The following incorporates several clarifications of NRC requirements for recognition of the ABR certification process.
- The ABR will only admit, for examination, candidates who have a minimum of 700 hours of training in the topics described in 10 CFR 35.390 (b)(1)(i)(A) through 10 CFR 35.390 (b)(1)(i)(E), as well as supervised work experience as outlined in 10 CFR 35.390 (b)(1)(ii)(A) through 10 CFR 35.390 (b)(1)(ii)(G)(2), and (3) training under an Authorized User (AU) for the oral administration of 131I requiring a written directive in quantities greater than 1.22 Gigabecquerels (33 millicuries) and parenteral administration of any beta emitter or a photon-emitting radionuclide with photon energy of < 150 KeV, for which a written directive is required. The work experience outlined in CFR 35.390 (b)(1)(ii) must be obtained under the supervision of an AU who meets the requirements in 10 CFR 35.390 or equivalent Agreement State requirements. A supervising AU who meets the requirements in 35.390(b) must also have experience in the oral administration of sodium iodide 131I, for which a written directive is required and the parenteral administration of any beta emitter, or a photon-emitting radionuclide with a photon energy less than 150 KeV, for which a written directive is required. Instruction may take place as part of the RRC-required courses in medical physics, radiation and cancer biology, and clinical radiation oncology, or a rotation in nuclear radiology.
- This training and supervised work experience must include all NRC-required items related to the safe handling, administration, and quality control of the radionuclide doses used in clinical radiation oncology and nuclear radiology. The Federal Register provides a comprehensive list of these items. ABR testing will cover topics that include radiation safety, radionuclide handling, quality assurance, treatment planning, and the clinical use of unsealed byproduct material for which a written directive is required, as well as manual brachytherapy, remote afterloading brachytherapy, stereotactic radiosurgery, and external beam therapy. Such items will be included on both the computer-based and oral examinations.
- ABR Certification will include satisfying the requirements for AU status as specified in 35.390(b)1(ii)(G)(2) and in 35.390(b)1(ii)(G)(3). To meet the requirements as an AU, residents must participate in three cases involving oral administration of > 33 mCi of 131I and three cases involving the parenteral administration of any beta emitter, or a photon-emitting radionuclide with photon energy of < 150 KeV. Note that this category includes 131I-labeled antibodies and 131I MIBG.
- The specific dates on which experiences with oral 131I and parenteral therapy occur and a case description should be kept in a log by each resident. Click here to download the log.